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ABSTRACT
As medicine advances toward a more personalized
model, the significance of genetic information is growing
exponentially. While unlocking the genetic code has
advanced the state of medicine, it has also reinvigorated
the debate over the boundaries of patentable subject
matter. The potential clash between having access to stateof-the-art medicine and protecting intellectual property
investments came to a head in the case, Association of
Molecular Pathology v. USPTO (“Myriad”). This Article
analyzes the legal opinion rendered by the district court
through the unique lens of genetic exceptionalism—a
concept previously reserved to social science and public
policy. Then, this Article analyzes Judge Sweet’s
unprecedented incorporation of genetic exceptionalism into
the Patent Act by first tracing the historical roots of the
exceptionalism doctrine and then dissecting the Myriad
decision through that historical lens. As it stands at
publication, it has yet to be seen whether the Supreme
Court will similarly adopting a novel interpretation of the
*

Kristen L. Burge has a B.S. in Neuroscience from Vanderbilt University
and a J.D. from Cumberland School of Law. After graduating magna cum laude
from Cumberland, Kristen went on to earn an LL.M. in Intellectual Property
Law and Policy at the University of Washington School of Law. Kristen is
currently a member in good standing of the Washington State Bar Association.

502

WASHINGTON JOURNAL OF LAW, TECHNOLOGY & ARTS [VOL. 8:4

Patent Act that incorporates genetic exceptionalism into
the Act’s subject matter restrictions.
TABLE OF CONTENTS
Introduction ..................................................................................503
I. Changing the Face of Medicine One Strand at a Time:
How Genetic Information is Altering the Practice of
Medicine ...............................................................................504
A. Defining Personalized Medicine ......................................504
B. The Science Underlying Genetics and Personalized
Medicine ........................................................................507
II. Patenting the Tools of Personalized Medicine: A Look
at the Impact of Genetic Patents on Patient Care .................509
III. Gene Patents: Does One Size Fit All? ..................................513
A. cDNA Patents ..................................................................514
B. EST Patents ......................................................................515
C. SNP Patents ......................................................................515
D. Patents on DNA Tests ......................................................516
E. Patents on DNA Diagnostic Algorithms ..........................517
IV. Genetics and the Law: An Overview of Subject Matter
Patentability Preceding Myriad ............................................518
V. Begging the Question: Does Genetic Exceptionalism
Have a Place in the Patent Act? ............................................522
A. The History of Genetic Exceptionalism in Social
Science and Public Policy .............................................522
B. Power Play from the Bench: Myriad’s Insertion of
Genetic Exceptionalism into the Patent Act ..................527
1. Background of BRCA1/2 and the Myriad
Litigation ................................................................528
2. A Closer Look at Judge Sweet’s Analysis in the
Myriad Decision .....................................................531
3. Genetic Exceptionalism Transcribed into Legal
Principle: Isolated DNA is not “Markedly
Different” from Native DNA .................................536
Conclusion ...................................................................................540

2013]

PERSONALIZED MEDICINE, GENETIC EXCEPTIONALISM,
AND THE RULE OF LAW

503

INTRODUCTION
Judge Sweet’s decision in Association of Molecular Pathology
v. USPTO (“Myriad”) 1 has reinvigorated the longstanding debate
of whether genes qualify for patent protection and whether
granting such protection does more harm to patients than good for
innovation. In a health care system moving more toward
personalized medicine, the resolution of these questions is vital for
the stability—and possibly the survival—of genetic innovation.
Myriad has the potential to greatly impact the way personalized
medicine is administered to patients by increasing access to more
at-risk patients and decreasing the cost of genetic testing. On the
other hand, the decision could be a potential setback to genetic
innovation that results in more harm to patients by stifling research
incentives. Regardless, stakeholders on both sides of the debate are
eagerly awaiting the appeal that will provide some stability in an
unsettled area of patent law.
There is no disagreement that since its discovery, DNA has
captivated audiences from the science, medical, ethical, and legal
fields, at times rising DNA to a near-reverent status. Despite the
promise that genetic science holds, the science is susceptible to
abuse, as has been demonstrated by the history of eugenics and
1

702 F. Supp. 2d 181 (S.D.N.Y. 2010). The procedural history of this
case—following Judge Sweet’s opinion in district court—is complicated. The
Federal Circuit first affirmed in part and reversed in part the lower court’s
decision in Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office,
653 F.3d 1329 (Fed. Cir. 2011) (reversing the lower court’s decision on gene
patentability by holding, among other things, that human genes are eligible
patent matter). Certiorari was granted by the United States Supreme Court, only
to have the case remanded back to the Federal Circuit for reconsideration. See
Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012).
After the Federal Circuit reviewed the case, the Supreme Court again granted
certiorari, limiting the issue to whether human genes are patentable. See Ass’n
for Molecular Pathology v. U.S. Patent and Trademark Office, 689 F.3d 1303
(Fed. Cir. 2012) and Ass’n for Molecular Pathology v. Myriad Genetics, Inc,
133 S. Ct. 694 (Nov. 30 2012) (certiorari granted in part). As it stands, the
parties have until March 2013 to file their briefs on the merit. For an up-to-date
status of the case as it proceeds through the Supreme Court, visit the case on the
Scotus Blog, available at http://www.scotusblog.com/case-files/cases/
association-for-molecular-pathology-v-myriad-genetics-inc/.
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ethnically targeted genetic screening programs. It is this
unharnessed power to do both good and bad that has directed
scientists, academia, and policy makers alike to treat genetic
information differently than other scientific knowledge, resulting
in “genetic exceptionalism.” Until the Myriad decision, however,
genetic exceptionalism did not exist as a legal principle under the
Patent Act, but was instead relegated to areas of discrimination,
privacy, and insurance.
To better understand Myriad’s impact on personalized
medicine and the progeny of gene patents flowing from the
genome, it is helpful to first understand basic genetic science, the
development of genetic exceptionalism in other contexts, the
various types of gene patents, and the existing law on subject
matter patentability. Part I of this Article begins with an overview
of personalized medicine and its relation to genetic science. Parts
II and III discuss the impact of patenting these genetic tools and
the types of patent protection falling within the catch-all category
of “gene patents.” In Part IV, the Article provides a summary of
the precedent governing the subject matter patentability
requirement. Finally, Part V addresses Judge Sweet’s incorporation
of genetic exceptionalism into the Patent Act by first tracing the
historical roots of the exceptionalism doctrine and then dissecting
the Myriad decision through that historical lens. After doing so, the
Article concludes that the court in Myriad inappropriately adopted
genetic exceptionalism as a legal principle on patentability instead
of leaving the gene patent policy decision to Congress.
I. CHANGING THE FACE OF MEDICINE ONE STRAND AT A TIME:
HOW GENETIC INFORMATION IS ALTERING THE PRACTICE OF
MEDICINE
A. Defining Personalized Medicine
What does the ambiguous phrase “personalized medicine”
actually mean? After all, doctor-patient relationships have
traditionally been of a personal nature. New advances in
technology have altered this traditional doctor-patient approach to
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treatment 2 and solidified “personalized medicine” as a term of art.
Building on the traditional doctor-patient relationship, personalized
medicine moves health care one step further by providing
physicians with a more precise tool to evaluate, diagnose, and treat
patients. Beyond promising better health outcomes for individual
patients, personalized medicine also has the potential to transform
the entire health care delivery infrastructure into a more efficient,
cost-effective system. 3
Despite being a recognized term of art, “personalized
medicine” has multiple definitions. On the literal end of the
spectrum, personalized medicine refers to the development of stem
cell based therapies that are specifically tailored to an individual. 4
In this context, doctors would use cloned stem cells—embryonic or
adult—to generate additional cells, tissues, or organs to circumvent
the inherent risks associated with individual transplantations. 5
On the other end of the spectrum, personalized medicine is cast
more broadly, referring to technologies and treatments that can be
administered to a subset of the population based on common
characteristics found in DNA and environmental factors. More in
line with this broader definition, the Personalized Medicine
2

See, e.g., Kent Bottles, The Doctor/Patient Relationship for the 21st
Century, THE PHYSICIAN EXECUTIVE 10-14 (Sep.-Oct. 2001), available at
http://www.kentbottles.com/pdfs/Doctor-Patient-Relationship-for-the-21stCentury.pdf (discussing different views of the doctor/patient relationship).
3
See generally James P. Evans et. al., Preparing for a Consumer-Driven
Genomic Age, 363 NEW ENG. J. MED. 1099 (2010) (discussing personalized
health care in the direct-to-consumer genetic testing context); Eric D. Green &
Mark S. Guyer, Charting a Course for Genomic Medicine from Base Pairs to
Bedside, 470 NATURE 204 (February 2011) (discussing a 2011 vision for
moving towards an era of genomic medicine); Margaret A. Hamburg & Francis
S. Collins, The Path to Personalized Medicine, 363 NEW ENG. J. MED. 301
(2010) (discussing the hurdles in moving from concept to clinical use); The Case
for Personalized Medicine, PERSONALIZED MEDICINE COALITION,
http://cllcanada.ca/2010/pdfs/TheCaseforPersonalizedMedicine_5_5_09.pdf
(discussing the benefits of personalized medicine and the necessary steps for
widespread implementation).
4
See Matthew Herder, Patents & the Progress of Personalized Medicine:
Biomarkers Research as Lens, 18 ANNALS HEALTH L. 187, 190-91 (2009).
5
Id. at 190. Currently embryonic stem cell therapy is in its nascent stage
and not a realistic therapeutic option.

506

WASHINGTON JOURNAL OF LAW, TECHNOLOGY & ARTS [VOL. 8:4

Coalition describes the emerging practice as follows:
Personalized medicine uses new methods of
molecular analysis to better manage a patient’s
disease or predisposition toward a disease. It aims
to achieve optimal medical outcomes by helping
physicians and patients choose the disease
management approaches likely to work best in the
context of a patient’s genetic and environmental
profile. Such approaches may include genetic
screening programs that more precisely diagnose
diseases and their sub-types, or help physicians
select the type and dose of medication best suited to
a certain group of patients. 6
Other definitions go even further to dispel the potential
misunderstanding surrounding the term “personalized.” For
instance, the President’s Council of Advisors on Science and
Technology stressed that personalized medicine “does not literally
mean the creation of drugs or medical devices that are unique to a
patient but rather the ability to classify individuals into
subpopulations that differ in their susceptibility to a particular
disease or their response to a specific treatment.” 7
In other words, personalized medicine interpreted broadly
enables physicians to provide better diagnoses and earlier
interventions, to engage in more effective drug development, and
to implement more effective therapies for various subsets of
patients who share the same genetic variations. 8

6

Personalized Medicine: An Introduction, PERSONALIZED MEDICINE
COALITION,
http://www.personalizedmedicinecoalition.org/sites/default/files/
personalmed_backgrounder.pdf.
7
Priorities for Personalized Medicine, President’s Council of Advisors on
Science and Technology (September 2008), http://www.whitehouse.gov/
files/documents/ostp/PCAST/pcast_report_v2.pdf.
8
Id. Because this paper focuses primarily on gene patents, the term
personalized medicine should be understood in the broader context as defined by
the Coalition and the President’s Council.
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B. The Science Underlying Genetics and Personalized Medicine
Genetic science continues to revolutionize the practice of
medicine by enabling treatment tailored to individual patients and
providing insight to better therapeutic approaches. Although many
patients utilize personalized medicine at some point over the
course of their medical treatment, not all patients understand the
science behind such treatment. While understanding the basics of
genetic science and the types of patents currently available for the
countless discoveries in the field would aid the reader’s
understanding of the genetic impact on medicine, an in-depth
discussion of this complex science is beyond the scope of this
paper. 9 Instead, this Article will provide a basic explanation from a
patient’s perspective: what are genes and how are they patented?
This section will define the key terms and introduce the basic
scientific foundations of genetics, moving into an overview of the
various categories of patents that collectively are referred to as
“gene patents.”
The genomic structure is best understood by explaining the
different parts of DNA and how its components direct the
formation of proteins. 10 DNA (deoxyribonucleic acid) is a double
helix structure created by two chemically-bonded strands that
9

See, e.g., Alan E. Guttmacher & Francis S. Collins, Genomic Medicine – A
Primer, 347 N. ENG. J. MED. 1512-20 (2002); W. Gregory Feero & Alan E.
Guttmacher, Genomic Medicine – An Updated Primer, 362 N. ENG. J. MED.
2001-11 (2010); Wylie Burke, Genetic Testing, 347 N. ENG. J. MED. 1867-75
(2002).
10
Many articles go into great detail on the structure of DNA and its
corresponding science. See, e.g., Eric D. Zard, Note, Patentability of Human
Genetic Information: Exploring Ethical Dilemmas Within the Patent Office and
Biotechnology’s Clash with the Public Good, 6 U. ST. THOMAS L.J. 486-490
(2009); Lorelei Perez Westin, Note, Genetic Patents: Gatekeeper to the
Promised Cure, 25 T. JEFFERSON L. REV. 271, 276-79 (2002). Similarly, the
Federal Circuit has discussed molecular genetics in greater depth. See, e.g., In re
Deuel, 51 F.3d 1552, 1554-56 (Fed. Cir. 1995); Amgen, Inc. v. Chugai Pharm.
Co., Ltd., 927 F.2d 1200, 1207-08 (Fed. Cir. 1991); In re O’Farrell, 853 F.2d
894, 895-99 (Fed. Cir. 1988). This Article will not rearticulate the scientific
foundation in as great detail, but will rather provide sufficient background to
understand the gene patents and their relationship with genetic exceptionalism.
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stores and encodes an organism’s genetic information. 11 Each
DNA strand contains four base molecules (A, G, C, and T) that
serve as the building blocks. 12 Before the cell can make the
protein, the DNA strand must undergo three processes: (1) copying
the DNA strand into RNA (transcription); (2) removing or splicing
of the inactive regions (introns) and connecting the active regions
(exons); and (3) translating the RNA (ribonucleic acid) into its
corresponding amino acids. 13 When joined together, these amino
acids fold into unique three-dimensional shapes that determine the
property and function of the protein in the body. 14
While the human genome contains more than three billion base
pairs, 15 only two percent of these base pairs represent the 20,000 to
25,000 genes present in the human genome. 16 In comparing human
11

Wylie Burke, Genetics Primer, NATIONAL ASSOCIATION OF WOMEN
JUDGES, GENOME JUSTICE, September 2005, 1-14.
12
Id.
13
The following figure, a reproduction of Figure 14.5 from DAVID KROGH,
BIOLOGY: A GUIDE TO THE NATURAL WORLD 249 (5th ed., 2005), depicts the
two processes for decoding genetic information:

14

There are typically three regions that are relevant to genetic patents: (1)
the exon region (coding region of the gene); (2) the promoter and terminating
regions of a gene (which mark the beginning and the end of gene); and the (3)
intron region (non-coding regions that are spliced or removed during the
transcription phase). See Mark A. Chavez, Gene Patenting: Do the Ends Justify
the Means, 7 COMPUTER L. REV. & TECH. J. 255, 256 (2003).
15
The human genome refers to the complete set of DNA from the combined
chromosomes. See The Science Behind the Human Genome Project: Basic
Genetics, Genome Draft Sequence, and Post-Genome Science, HUMAN GENOME
PROJECT INFORMATION (Mar. 26, 2008) http://www.ornl.gov/sci/techresources/
Human_Genome/project/info.shtml.
16
How Many Genes Are in the Human Genome?, HUMAN GENOME
PROJECT INFORMATION (Sept. 19, 2008) http://www.ornl.gov/sci/techresources/
Human_Genome/faq/genenumber.shtml. Currently, the average gene is
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genomes, scientists have discovered that humans share
approximately 99.9 percent of the same code, resulting in only .01
percent variation between human genomes. 17 Scientists have
identified 1.4 million locations where these single-base variations
occur. 18 These variations are referred to as single nucleotide
polymorphisms, or “SNPs.” 19
Depending on where the variation occurs, the mutation(s) may
result either in minor changes that account for the normal range of
characteristic like hair color, height, or medication response, or in
more profound changes that are responsible for various forms of
genetic diseases. 20 While a single mutation may cause a handful of
diseases, the majority of diseases are multifactorial, depending on
a complex interaction of multiple genes and numerous
environmental factors. 21
II. PATENTING THE TOOLS OF PERSONALIZED MEDICINE:
A LOOK AT THE IMPACT OF GENETIC PATENTS ON PATIENT CARE
Each step towards understanding the human genome fortifies
the bridge between DNA code and a patient’s bedside by creating
new possibilities in personalized medicine. With the completion of
the Human Genome Project, researchers have unlocked the key to
a wealth of genetic information. But discovering the function and
relationship of genes and translating these discoveries into
approximately 3,000 bases, with the largest known gene having 2.4 million. And
of the known genes, scientists can identify the function for only approximately
50 percent.
17
Burke, supra note 9, at 4.
18
Id.
19
Id.
20
Id. SNPs help determine the likelihood that a person will develop a
disease during his or her lifetime.
21
See id. at 7, 12. The media coverage has influenced the public’s
perception of genetic diseases, often oversimplifying the causation between a
mutation and a disease and overemphasizing the determinative effect of a
genetic mutation. Diseases caused by single gene mutations can be broken down
into autosomal dominant, autosomal recessive, and X-linked recessive disorders.
Chromosomal conditions, another subset of genetic diseases, are caused by a
deficiency or excess of chromosomal material. Id. at 9-11.
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beneficial treatment is an ongoing, complex endeavor. Currently,
there are over 6,000 diseases that can be traced to a single gene, 22
while there are thousands of other conditions that are linked to
genetic variations in multiple genes and interactions with
environmental factors. As scientists better understand these
complex genetic interactions, further progress can be made in the
development of diagnostic tools, prevention techniques, and
therapeutic treatments. 23
With the progress in personalized medicine comes the desire to
protect the intellectual property associated with such
advancements. The impetus behind the U.S. patent law system has
always been the careful balancing between the competing interests
of incentivizing innovation, encouraging the disclosure of
inventions for the public good, and fostering competition. The
framers of the U.S. Constitution were mindful of these tradeoffs in
drafting Article I § 8, which provides that Congress shall have the
power “[t]o promote the Progress of Science and useful Arts, by
securing for limited Times to Authors and Inventors the exclusive
Right to their respective Writings and Discoveries.” 24 America’s
founding fathers understood that granting an exclusive right for a
period of time may justify an otherwise undesired monopoly so
long as the exclusive right provided sufficient incentives to invest
in research and development that would otherwise not come to
fruition absent the incentive. In exchange for this period of
exclusivity, however, the patentee must contribute to the public a
useful, novel, non-obvious invention–disclosing sufficient
information for a person skilled in the arts to practice the
invention. 25
Understanding that innovation and ongoing discovery is
22

Melissa
Conrad
Stoppler,
Genetic
Diseases
Overview,
(May
11,
2010),
http://www.medicinenet.com/
MEDICINENET.COM
genetic_disease/article.htm.
23
Eric D. Green & Mark S. Guyer, Charting a Course for Genomic
Medicine from Base Pairs to Bedside, 470 NATURE 204 (2011); see also Ethical,
Legal & Social Issues: Gene Testing, HUMAN GENOME PROJECT INFORMATION
(July 7, 2010) http://www.ornl.gov/sci/techresources/Human_Genome/elsi/
patents.shtml.
24
U.S. CONST. art. I, § 8, cl. 8.
25
See 35 U.S.C. §§101-103, 112 (2003).
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imperative to personalized medicine’s success, numerous
stakeholders have raised concerns that granting genetic patents
may substantially impede necessary scientific research and block
access to therapeutic treatments. 26 As a basis for these public
policy concerns, critics argue that the twenty years of protection
provided to the patent holder from the date of filing enables the
patent holder to prevent others from researching the patented gene
and from performing diagnostic testing procedures on patented
variations of the gene. 27 Critics maintain that even if a patent
holder is willing to license the patent(s), researchers have a
difficult time locating the owner of the patent rights. 28 Moreover,
because U.S. patent law permits patent issuance for gene fragments
and single nucleotide variations (see discussion on the types of
gene patents, infra), critics argue that licensees incur higher
transaction costs to obtain multiple licenses associated with one
gene. 29
In an effort to assess whether gene patents truly inhibit
research, health and science researcher David Blumenthal 30
conducted several surveys that targeted both academics and
commercial scientists involved with genetic research. He found
that “[o]ne of every five medical scientists has delayed publication
of research results for at least half a year in order to protect
26

See Marisa Noelle Pins, Impeding Access to Quality Patient Care and
Patient Rights: How Myriad Genetics’ Gene Patents Are Unknowingly Killing
Cancer Patients and How to Calm the Ripple Effect, 17 J. INTELL. PROP. L. 377
(2010).
27
See Eric Zard, Comment, Patentability of Human Genetic Information:
Exploring Ethical Dilemmas Within the Patent Office and Biotechnology’s
Clash With the Public Good, 6 U. ST. THOMAS L.J. 486, 504 (2009).
28
Id.
29
Id.
30
David Blumenthal, M.D., M.P.P., was appointed on March 20, 2009, by
the Obama Administration to serve as the National Coordinator for Health
Information Technology. In this capacity, Dr. Blumenthal will lead “the
implementation of a nationwide interoperable, privacy-protected health
information technology infrastructure.” U.S. Dept. of Health & Human Services,
HHS Names David Blumenthal As National Coordinator for Health Information
Technology (March 20, 2009), available at http://www.hhs.gov/news/
press/2009pres/03/20090320b.html.
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financial interests.” 31 He also found that “twenty-eight percent of
the geneticists surveyed reported that they were unable to duplicate
published research because other academic scientists refused to
share information, data, or materials,” 32 thereby preventing
scientists from verifying the studies.
Further compounding the problem of gene patents is the
“patent thicket”—a term critics use to refer to the multiple patents
on various components of a gene—which, according to some
critics, “may be stifling life-saving innovations further downstream
in the course of research and product development.” 33 In other
words, if research scientists must acquire multiple licenses from
multiple parties to conduct research on any given gene, then the
cost of researching gene therapy is greater and the research itself is
at risk of being derailed by a patent holder who refuses to license a
necessary input to the research. 34
While some critics concede that a level of patent protection is
necessary for incentivizing research, they suggest that the patent
system is offering protection at the wrong stage in the development
process. 35 By issuing patents early in the development process
when little is understood about the role the gene plays, a patent
holder can assert the patent against later discovered mutations or
genetic associations when more is understood about the gene’s role
in genetic diseases. 36 Arguably, the patent system grants the
equivalent of a “hunting license” to the pioneering scientist,
rewarding the search without compensating later discoveries that
31

Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial
Incentives With Health Needs, 2 HOUS. J. HEALTH L. & POL’Y 65, 81 (2002)
(summarizing findings in David Blumenthal et al., Withholding Research
Results in Academic Life Sciences, 277 JAMA 1224, 1224 (1997)).
32
Id. (citing David Blumenthal et al., Data Withholding in Academic
Genetics, 284 JAMA 473, 477 (2002)).
33
Id. at 85 (quoting Michael A. Heller and Rebecca S. Eisenberg, Can
Patents Deter Innovation? The Anticommons in Biomedical Research, 280 SCI.
698, 701 (1998)).
34
See id. at 85-86.
35
See id.
36
See id. at 87-88. But consider that some people, including Steven Shavell,
argue that awarding patents early in the process prevents excess duplicative
investment.
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result in a useful application. 37 As Justice Abraham Fortas once
summarized, “a patent may confer power to block off whole areas
of scientific development, without compensating benefits to the
public.” 38
Finally, gene patents arguably deprive patients the access to
reliable genetic tests and therapies that would otherwise be
available. Because some patent holders exclusively license their
patent, a genetic test may be permitted at one laboratory, leaving
the patient with no means for getting a second opinion.
III. GENE PATENTS: DOES ONE SIZE FIT ALL?
This Article’s genetic primer has focused thus far on how DNA
works in its natural, non-patentable state. To be patentable, an
inventor must “transform” genetic information into a non-natural
form to circumvent the rule against patenting products of nature. 39
After taking steps to isolate, purify, or modify the genetic
information, the inventor can claim the resulting product as an
invention because the resulting product is chemically different
from the product in nature. 40 In other words, the patent is not
issued on the gene found in the body, but rather on man-made
DNA molecules. 41
Generally, genetic patent claims relate to one of the following
four categories found to satisfy the patentability standards prior to
Myriad:
(1) Whole genes or parts of them, (2) proteins that
the genes encode as well as their function in
organisms, (3) vectors used for the transfer of genes
37

Id. at 88.
Id. at 88 (quoting Brenner v. Manson, 383 U.S. 519, 536 (1966)).
39
See, e.g., Parker v. Flook, 437 U.S. 584 (1978); Diamond v. Diehr, 450
U.S. 175 (1981).
40
Id. Isolating DNA refers to the process of removing the DNA from its
natural environment in the body, while purifying DNA refers to removing the
non-coding regions of the DNA (e.g. cDNA). See John Conley & Dan Vorhaus,
When the Grass Eats the Cows, 23 GENEWATCH 8 (Oct.-Dec. 2010).
41
See Sharon Terry, Why Banning Patents Would Hurt Patients, 23
GENEWATCH 24 (Oct.-Dec. 2010).
38
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from one organism to another, or (4) genetically
modified cells or organisms, processes used for the
making of genetically modified products and the
uses of genetic sequences or proteins for genetic
tests. 42
The patents are generally issued as “compositions of matter” or
“method-of-use” patents, and although sometimes erroneously
interpreted as patenting the gene itself, the patent only covers
genetic information that has been isolated and purified. 43
A. cDNA Patents
Complementary DNA (cDNA) is a synthetic copy of an
isolated section of DNA that includes only the coding-region for a
protein as opposed to the entire gene as it is found in the body. 44
Scientists take the mRNA (which is copied DNA minus the noncoding regions) and convert it into a new DNA molecule through
reverse transcription (cDNA). 45 Structurally and functionally
different from genes found in nature, cDNA molecules can be used
to produce large quantities of human protein in non-human species,
to identify disease-causing mutations for diagnostic testing, to treat
genetic disorders (gene therapy), and to enable new discoveries
with their use as chemical reagents and research tools. 46 Although
critics of cDNA patents assert that the information contained in
cDNA is identical to naturally occurring DNA, even those critics
acknowledge that naturally occurring DNA cannot be used for
commercial diagnostic testing and research. 47
42

E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of the
Political Storm, http://www.theinnovationpartnership.org/data/ieg/documents/
cases/TIP_Myriad_Legal.pdf (working document).
43
Id.
44
See Kevin Noonan, Why Genes Must Remain Eligible for Patenting, 23
GENEWATCH, 24, 30 (Oct.-Dec. 2010).
45
Id.
46
See Terry, supra note 41.
47
See Magdalina Gugucheva, The Physical Embodiment of Information, 23
GENEWATCH 26-27 (Oct.-Dec. 2010). Vectors, which are larger molecules with
integrated cDNA, that can be used to insert genes into other cells, are also
patentable.
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B. EST Patents
Expressed sequence tags (ESTs) are fragments of the cDNA
molecule that are approximately 300-500 base pairs long,
representing approximately 10 to 30 percent of the average cDNA
molecule. 48 In practice, ESTs are used as research tools to map and
discover entire genes in a fraction of the time it would take without
the aid of these markers. Advocates for EST patenting claim that
there are several uses for ESTs, which include: (1) serving as a
molecular marker for mapping genomes; (2) measuring the level of
mRNA in a tissue sample; (3) providing primers for polymerase
chain reaction processes; (4) identifying polymorphisms; (5)
isolating promoters via chromosome walking; (6) controlling
protein expression; and (7) locating genetic molecules of other
plants and organisms. 49 In 2005, the Federal Circuit addressed the
patentability of ESTs in In re Fisher. 50 Focusing on the utility
requirement under § 101 of the Patent Act, the court invalidated
the patent for lacking “specific and substantial utility.” 51 Without
digressing into a utility discussion, it is sufficient for this Article’s
purpose to understand that EST patents must claim a known
correlation between the EST and an identified underlying gene to
be patentable. 52 Strictly speaking, the EST must be more than a
mere research intermediary with no immediate, well-defined
benefit to the public. 53
C. SNP Patents
Of the patents that are collectively referred to as “gene
patents,” SNP patents are arguably the most controversial because
48

Genetics and Patenting, HUMAN GENOME PROJECT INFORMATION (July 7,
2010)
http://www.ornl.gov/sci/techresources/Human_Genome/elsi/
patents.shtml.
49
See In re Fisher, 421 F.3d 1365, 1369-74 (Fed. Cir. 2005) (discussing the
uses for ESTs proffered by Fisher).
50
Id.
51
Id.
52
See id. at 1372-73.
53
Id.
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SNP patents permit the patentee to claim one “letter” of a sentence.
As previously discussed, SNPs are unlike cDNA and EST
fragments because they represent a genetic mutation (or variation)
in only one nucleotide base in a genetic sequence. 54 These minor
variations can have a major impact on the way that humans
respond to disease, environmental factors, or pharmaceuticals and
medical treatment. 55 Typically, SNP patents include claims for the
method of determining a patient’s susceptibility to a disease by
detecting a particular SNP in a known gene and for the isolated
SNP molecule itself. 56
D. Patents on DNA Tests
The relationships between genetic mutations and diseases
allow practitioners to tailor medical diagnoses and treatment to
individual patients. Once a gene is discovered, scientists then work
to develop a complementary test to screen individuals for the
genetic mutation associated with a disease. 57 Genetic tests offer a
window to a person’s genetic make-up, making it possible to
confirm suspected diagnoses, to predict likelihood of future illness,
to detect carrier status in unaffected individuals, and to evaluate a
person’s response to medical treatment. 58 The tests differ in the
manner by which they identify genetic variations. For example,
some tests utilize short pieces of DNA, called probes, to seek out a
complementary sequence to the mutated gene which then binds to
the sequence if present. 59 Another type of genetic testing directly
compares the patient’s DNA sequence to a normal version of the
sequence, looking for any differences between the two
sequences. 60 Finally, other genetic tests detect gene products, such
54

See Genome Project Information, Ethical, Legal & Social Issues: Gene
Testing, HUMAN GENOME PROJECT INFORMATION (July 7, 2010)
http://www.ornl.gov/sci/techresources/Human_Genome/elsi/patents.shtml.
55
Id.
56
Id.
57
Genetic Testing, NATIONAL HUMAN GENOME RESEARCH INSTITUTE (Jan.
10, 2013), http://www.genome.gov/10002335.
58
Id.
59
Id.
60
Id.
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as an enzymes or proteins, for determining whether a gene
variation is present. 61 Beyond method patents for analyzing a
person’s DNA, genetic testing patents may also cover the physical
testing kits that contain the necessary materials to perform the
test. 62
E. Patents on DNA Diagnostic Algorithms
Genetic patents have also been issued for algorithms that
compare known risks with multiple genetic variations. 63 These
method patents straddle the line between an abstract idea and an
invention. 64 When the algorithm uses information derived from
multiple variations and gives different weight to known risks, the
algorithm is likely to be patentable subject matter. 65 In this case,
scientists can invent around the patented algorithm by creating a
different model of analysis. 66 The issue of patentability is more
questionable when the diagnostic algorithms use an “assay-andcorrelate” model, which analyzes simple levels of physiological
substances. 67 For these algorithms, it much more difficult—if not
impossible—to design around the patented method.

61

Id.
Eileen M. Kane, Patent-Mediated Standards in Genetic Testing, 2008
UTAH L. REV. 835, 846 (2008).
63
Michael J. Shuster & Pauline Farmer-Koppenol, Patent Strategy for
Personalized Medicine in Light of Bilski, BILSKYBLOG.COM (2010),
http://www.bilskiblog.com/files/07-19-10_patent-strategy-for-personalizedmedicine-bilski-3.
64
Id.
65
Id.
66
Id.
67
Id. Algorithms are also used in developing synthetic DNA with computer
software and are patentable. For example, “patents have already been granted on
many of the processes and products involved in synthetic biology, including
patents on methods for building synthetic DNA, synthetic genes and DNA
sequences, synthetic pathways, synthetic proteins and amino acids, and novel
nucleotides that replace the letters of DNA.” Eric Hoffman & Jaydee Hanson,
Synthetic Biology: The Next Wave of Patents on Life, 23 GENEWATCH 39, 40
(Oct.-Dec. 2010).
62
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IV. GENETICS AND THE LAW: AN OVERVIEW OF SUBJECT
MATTER PATENTABILITY PRECEDING MYRIAD
The watershed case invalidating Myriad Genetics’ gene patents
was not the first to address gene patents, albeit perhaps the first to
directly attack the patents under the subject matter requirement. 68
Patent law’s history is fraught with cases that courts can draw on
for the gene patentability analysis, dating as far back as the late
1800s. 69 The earlier cases addressing biotechnology patents
focused primarily on the novelty and obviousness prongs of
patentability. 70 It was not until after the Patent Act of 1952,
however, that courts recognized the requirements of subject matter,
novelty, and non-obviousness were wholly separate inquiries. 71
The purification doctrine 72 has long been the linchpin for
justifying gene patents. In 1874, the Supreme Court addressed the
validity of a patent on purified cellulose used to make paper. 73 The
Court reasoned that because the product was not substantially
different than the naturally occurring product either in form or
substance, the patent was invalid for lack of novelty. 74
Subsequent courts interpreted this decision to mean that
inventors could potentially patent purified or isolated products of
nature with a new commercial or therapeutic use. In the early
1900s, Parke-Davis & Co. v. Kalo Inoculant Co., decided whether
purified adrenaline could be patented. 75 In upholding the validity
68

Myriad Genetics is the company that holds the patents on BRCA1/2,
which are the patents the plaintiff sought to invalidate in the case referred to
herein as Myriad.
69
See Ashley McHugh, Invalidating Gene Patents: Association for
Molecular Pathology v. U.S. Patent & Trademark Office, 62 HASTINGS SCI. &
TECH. L.J. 185, 191-92 (2010).
70
See id.
71
See id.
72
The purification doctrine states that naturally occurring substances may
still be patentable, despite being products of nature, if the substance can be
isolated and purified from its naturally occurring state. See, e.g., Parke-Davis &
Co. v. H.K. Mulford Co., 189 F. 95 (S.D.N.Y. 1911).
73
American Wood-Paper Co. v. Fibre Disintegrating Co., 90 U.S. 566
(1874).
74
Id. at 593-96.
75
Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95 (S.D.N.Y. 1911).
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of the patent, the court reasoned that although the product was
naturally occurring, the purified version of adrenaline was “a new
thing commercially and therapeutically.” 76
Despite the trend of expansive subject matter, the Supreme
Court reigned in the scope of patentable subject matter for
naturally occurring products in its 1948 opinion in Funk Brothers
Seed Co. v. Kalo Inoculant Co. 77 At issue in Funk Brothers was
the validity of a patent held for a mixture of isolated bacterium,
which unlike its predecessor products, could be mixed without the
inhibitory effects owing to the inventor’s method of testing and
selecting noninhibitive strains. 78 The Court evaluated the patent
under the requirements set forth in 35 U.S.C. § 31, which
permitted issuance of a patent to, “[a]ny person who has invented
or discovered any new and useful art, machine, manufacture, or
composition of matter . . . .” 79 Interpreting the requirement of
“invention or discovery,” Justice Douglas provided that “[t]he
qualities [of the invention at issue] are the work of nature. Those
qualities are, of course, not patentable. For patents cannot issue for
the discovery of the phenomena of nature.” 80 The Court focused on
the properties of the bacterium, namely that they performed no
new function when mixed together and merely provided a more
efficient means of packaging for the purchaser. 81
Although seemingly supporting the position that genes (and
fragments) are entirely outside the scope of patentability as
products of nature, Justice Douglas’ oft-quoted statement for this
proposition must be narrowly read in light of the limited question
presented: whether the mixture was an “invention or discovery”
within the meaning of 35 U.S.C. § 31. The way the act was written,
the “invention or discovery” requirement stands separate from the
patentable subject matter requirement, which is embodied in the
76

Id. at 103.
333 U.S. 127 (1948).
78
Id. at 130-31.
79
35 U.S.C. § 31 (2000) (emphasis added).
80
Funk Brothers, 333 U.S. at 130.
81
Id. at 131-32 (“[T]he packages of mixed inoculants also hold advantages
for the dealers and manufacturers by reducing inventory problems and the
like.”).
77
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“art, machine, manufacture, or composition of matter” language.
The Court also provided additional language that suggests it was
not deciding the case on the subject matter prong of patentability:
Each of the species of root nodule bacteria
contained in the package infects the same group of
leguminous plants which it always infected. No
species acquires a different use. The combination of
species produces no new bacteria, no change in the
six species of bacteria, and no enlargement of the
range of their utility. . . . Their use in combination
does not improve in any way their natural
functioning. 82
Because the Funk Brothers analysis was directed at the
invention or discovery prong—not the subject matter prong—the
holding should be narrowly construed in subsequent cases. 83
Opponents of gene patents should not be quick to conclude that the
case prohibits patenting naturally occurring biological products
since the likely correct interpretation invalidates only those patents
that fail to apply the naturally occurring substance in a nonobvious way. 84
Indeed, Funk Brothers did not foreclose the door for patents on
naturally occurring substances despite Justice Douglas’
“phenomena of nature” reasoning. 85 In 1980, the Supreme Court
82

Id. at 131 (emphasis added).
See id. at 132 (“[W]e conclude that the product claims do not disclose an
invention or discovery within the meaning of the patent statutes, we do not
consider whether the other statutory requirements contained in 35 U.S.C. § 31,
R.S. § 4886, are satisfied.”) (emphasis added).
84
See John M. Conley & Roberte Makowski, Back to the Future:
Rethinking the Product of Nature Doctrine as a Barrier to Biotechnology
Patents, 85 J. PAT. & TRADEMARK OFF. SOC'Y 301 (2003).
85
See, e.g., Merck & Co. v. Olin Mathieson Chemical Corp., 253 F.2d 156,
164 (4th Cir. 1958). In 1958, the Fourth Circuit Court of Appeals upheld a
patent on purified vitamin B-12 based on the therapeutic and commercial value
of the biological product, noting that nothing in the language of the Patent Act
of 1952 prohibited the patenting of naturally occurring substances. Id. The court
found that compositions of matter necessarily included products of nature,
stating:
All of the tangible things with which man deals and for which
83
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decided the question whether a genetically modified organism was
patentable subject matter under the current Patent Act, 35 U.S.C. §
101. 86 Drawing from the purification doctrine, the Supreme Court
held that a genetically altered organism was patentable as a
“nonnaturally occurring” biological product. 87 The Court reasoned
that the genetically engineered bacterium—developed to break
down oil—was patentable under § 101 as a “manufacture” or
“composition of matter” because the altered product had
characteristics that did not exist in its native environment.88
Specifically distinguishing Funk Brothers, the Chakrabarty Court
held that the bacterium had “markedly different characteristics
from any found in nature and one having the potential for
significant utility.” 89 Unlike in Funk Brothers, the Chakrabarty
decision clearly speaks to the subject matter requirement.
Marking a turning point for the biotechnology industry,
Chakrabarty has since provided gene patent advocates with fodder
in the patentability debate. 90 By the close of the 20th century, the
patentability of isolated (or purified) naturally occurring products
was well-established, providing the biotechnology industry with
much-needed assurance that its emerging discoveries would be
protected by the U.S. patent system. 91 The USPTO issued
numerous gene patents under the purification doctrine without
dispute as to whether the subject matter was beyond the scope of
patentability, granting over 5,000 DNA patents and 16,000 relating

patent protection is granted are products of nature in the sense
that nature provides the basic source materials. The ‘matter’ of
which patentable new and useful compositions are composed
are composed necessarily includes naturally existing elements
and materials.
Id. at 161-62.
86
Diamond v. Chakrabarty, 447 U.S. 303 (1980).
87
Id. at 303.
88
See id. at 308-09.
89
Id. at 310.
90
See Gold, supra note 42; DAVID B. RESNIK, OWNING THE GENOME: A
MORAL ANALYSIS OF DNA PATENTING 1 (2004).
91
See id.
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to DNA in the two decades that followed this revolutionary
decision. 92
Despite the proliferation of DNA patents, none have been
invalidated for lack of subject matter. Instead, challenges to gene
patents focus primarily on the novelty, utility, and non-obviousness
requirements for patentability. 93
V. BEGGING THE QUESTION: DOES GENETIC EXCEPTIONALISM
HAVE A PLACE IN THE PATENT ACT?
A. The History of Genetic Exceptionalism in Social Science and
Public Policy
Several bioethicists and legal commentators have discussed the
role of genetic exceptionalism in the areas of privacy, insurance,
and discrimination laws, with some questioning whether the
special treatment of genetic information is necessary or even
beneficial. 94 Despite the body of literature replete with arguments
for and against gene patentability, genetic exceptionalism is
conspicuously absent from the debate. The recently decided case
invalidating Myriad’s BRCA1/2 patents, however, arguably
opened the door to a more nuanced application for genetic
exceptionalism: invalidating gene patents based primarily on a
gene’s unique function in nature as an information carrier. To
better understand how Judge Sweet’s legal analysis effectively
directs gene patents down the road to exceptionalism, it is first
92

Id.
Because this Article focuses solely on genetic exceptionalism’s influence
on the subject matter requirement for gene patents, the court decisions regarding
utility, novelty, obviousness, and enablement will not be discussed here.
Recognizing these requirements are equally important to gene patentability, the
Author suggests reading Lauren M. Nowierski, Note, A Defense of Patenting
Human Genome Sequences Under U.S. Law: Support For the Patenting of
Isolated and Purified Substances, 26 CARDOZO ARTS & ENT. L.J. 473 (2008),
for an in-depth overview of genetic patent challenges under these patentability
prongs. See also Conley, supra, note 40.
94
See, e.g., Sonia M. Suter, The Allure and Peril of Genetics
Exceptionalism: Do We Need Special Genetics Legislation?, 79 WASH. U. L.Q.
669, 671 (2001).
93
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necessary to understand the principle of genetic exceptionalism
and its historical development in American culture.
Genetic exceptionalism is a term that refers to the idea that
genetic information is qualitatively different from other health
information and raises separate social, ethical, and legal issues. 95
Both a fascination with the inherent power of genetic information
and the historical fear from genetics’ role in eugenics arguably
spawned the principle of genetic exceptionalism.
Despite its potential for providing improved patient care,
genetic information can be both “uniquely threatening and
susceptible to misuse.” 96 In an article assessing its allure, Professor
Sonia M. Suter traced genetic exceptionalism’s development from
its historical roots through the eyes of four key stakeholders: the
public, the media, scientists, and policy makers. 97 Since the
discovery of genes, the public and media have together elevated
genes’ status to an arguably overstated position of the “Holy Grail”
of predictive traits and patient well-being. Since the early 1960s,
the media has run rampant with coverage that suggests single
genes alone determine characteristics ranging from everything like
aggression to homosexuality, while often understating the role of
multi-gene and environmental interactions. 98
In the 1980s, popular culture was fixated on the advent of gene
therapy that promised to treat or prevent disease altogether, but
three decades later the public and medical community are still

95

Id. at 671.
Id.
97
Id. at 674-75.
98
See, e.g., Robert Wring, Our Cheating Hearts, TIME MAGAZINE, Aug. 15,
1994 (“[Genes] affect behavior by creating feelings and thoughts--by building
and maintaining the brain.”); DOROTHY NELKIN & M. SUSAN LINEE, THE DNA
MYSTIQUE: THE GENE AS A CULTURAL ICON 85 (1995) (quoting a New York
Times reporter as having said “evil is ‘embedded in the chromosomes that our
parents that our parents pass to us at conception.’”). In their book, authors
Nelkin and Linee suggest that popular culture’s “love affair” with the gene
draws from scientific principles, but fails to confine itself to DNA’s technical
boundaries. The authors detailed the debate over the criminal gene, which
gained traction in the early 1960s and continued throughout the decades in
media’s coverage of seemingly unexplainable crimes. See id. at 83-86.
96
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waiting for the promise to come to fruition. 99 As one author
comments, “Science reporters must first and foremost attract
readers, a difficult task when competing with more attentiongrabbing topics like war and pop culture. Likely in response to this
pressure, two trends have emerged in media coverage of genetics:
oversimplification and sensationalism.” 100
Prior to 1993, media coverage focused on newly discovered
genes, but as these discoveries became “old news,” the stories lost
their luster. 101 The media responded by shifting their angle to the
pitfalls and perils of genetics, reporting on cautionary tales of
discrimination and the proliferation of designer babies. 102
Regardless of whether the undulating media coverage currently
paints genetics with a brush or negative, the public’s impression
that genetics deserves a unique, tailored discourse has already been
solidified in the collective mind.
Throughout the ongoing discourse, the public and media have
not ignored the other side of the proverbial genetic coin.
Simultaneous with genetics’ elevation to its “Holy Grail” status
was the emergence of a historically-based distrust of genetics’
misuse. While the majority of the public most readily identifies the
eugenics movement’s apex with the Nazi experiments of World
War II, the principles of reproductive selection have existed since
the days of Darwin. 103And as evidenced by the oft-reviled United
99

See Gene Therapy, HUMAN GENOME PROJECT INFORMATION (Aug. 24,
2011),
http://www.ornl.gov/sci/techresources/Human_Genome/medicine/
genetherapy.shtml. Gene therapy remains in the experimental stage and has yet
to have a solidly successful clinical trial. The technology has not overcome the
difficulties presented by the short-lived nature of gene therapy, immune
responses in recipients, problems with viral vectors, and the complex nature of
multigene disorders.
100
Ellen Dupont, Diagnosing the Geno-Hype: Genetic Determinism in the
Mass Media, 5 THE SCI. IN SOC’Y REV. 20, 21 (Spring 2009).
101
Suter, supra note 94, at 678 n.1.
102
See Dupont, supra note 100; see also David A. Hyman, Lies, Damned
Lies and Narrative, 73 IND. L.J. 797 (1998) (discussing the power of anecdotal
evidence to shape public opinion); Mike Snider, How Genetics Can Be Used
Against You, USA TODAY, Nov. 17, 1993, at 9D, available at 1993 WL
6726460; Lisa Goldstein, If You Knew Your Child Would Be Born Deaf, S.F.
CHRON., Feb. 1, 1999, at A19.
103
Although deemed most prolific implementation of eugenics practice, the
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States Supreme Court case Buck v. Bell, 104 the eugenics movement
did not culturally confine itself. In fact, eugenics’ principles
manifested themselves as the underpinning rationale for the
Court’s upholding of compulsory sterilization in America. 105 Not
only did courts promulgate eugenics principles, so too did the
legislatures at both the federal and state level. In 1924, Congress
adopted the Federal Immigration Restriction Act to curb the
migration of persons thought to have defective genes. 106 States, on
the other hand, began implementing mandatory genetic screening
programs for African Americans in the 1970s, resulting in the
unintended, yet harmful stigmatization of the African American
population. 107 This brief history of the eugenics movement serves
only to illustrate the imbedded distrust present in the public’s
perception of genetic science.
Many scholars, researchers, and law makers alike have been
influenced by the media and the history of genetics as an
exceptional science in their quest for solutions to social issues and
policy making. As early as the 1970s, legislatures have crafted
laws that regulate genetic information separate and apart from
other medical information, 108 the most recent genetic-specific
legislation being the Genetic Information Nondiscrimination Act
signed into law by President Bush in 2008. 109 Contributing to the
Nazi regime by no means created the practice. The word “eugenics” was coined
in 1883 by Francis Galton to refer to the practice of improving the human race
by controlling reproduction. Martin S. Pernick, Eugenics and Public Health in
American History, 87 AM. J. PUB. HEALTH 1767 (1997). In 1922, the American
Society for Eugenics was founded in the United States to “stem the tide of
threatened race degeneracy,” and in 1927, the Supreme Court of the United
States justified the use of compulsory reproductive eugenics to sterilize those
deemed unfit for reproducing. Id. at 1769.
104
274 U.S. 200 (1927).
105
See id.
106
Paul Lombardo, Medicine, Eugenics, and the Supreme Court, 13 J.
CONTEMP. HEALTH L. & POL’Y 2 (1996).
107
Howard Markel, The Stigma of Disease: Implications of Genetic
Screening, 93 AM. J. MED. 209, 210-11 (1992).
108
Suter, supra note 94 at 670 n.1.
109
Genetic Information Nondiscrimination Act, H.R. 493 (110th Cong.
2008). GINA prohibits health insurance companies and employers from
discriminating against individuals based on genetic information, which includes
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driving force of the exceptionalism movement was the dedication
of “the largest expenditure of money for biomedical ethics and
health law in the country” to the study of the ethical, legal, and
social issues (ELSI) in genetic research. 110 This unprecedented
expenditure generated a vast body of literature and countless
studies dedicated exclusively to genetic issues, and “even if much
of the scholarship is not explicitly premised on notions of genetics
exceptionalism, . . . [it] intensifies the media’s attention to genetics
issues and public fear about genetics.” 111 While many of the same
threats for misuse and potential social consequences exist in other
disciplines, no other science has captivated the public with equal
pervasiveness as genetic science. 112
The confluence of lofty promises for cures, the trendy appeal
of the ethical issues, and the sordid history of misuse can explain
genetic exceptionalism in American culture. Traditionally, scholars
have analyzed genetic exceptionalism in the areas of employment
discrimination, insurance discrimination, and privacy laws. 113 The
family medical histories and information pertaining to an individual or family
member’s genetic tests and genetic services. Although several states had already
acted to protect against genetic discrimination, GINA served to set the minimum
level of protection afforded to individuals.
110
Suter, supra note 94, at 685 n.1 (quoting Robert Weir, Why Fund ELSI
Projects?, in GENES AND HUMAN SELF KNOWLEDGE: HISTORICAL AND
PHILOSOPHICAL REFLECTIONS ON MODERN GENETICS 189 (Robert F. Weir et al.
eds., 1994)).
111
Suter, supra note 94, at 685-86.
112
See Thomas H. Murray, Genetic Exceptionalism and “Future Diaries”:
Is Genetic Information Different from Other Medical Information, in GENETIC
SECRETS: PROTECTING PRIVACY AND CONFIDENTIALITY IN THE GENETIC ERA 60,
61 (Mark A. Rothstein ed., 1997); Suter, supra note 94. But see Eric T. Juengst,
FACE Facts: Why Human Genetics Will Always Provoke Bioethics 32 J.L. MED.
& ETHICS 267 (2004) (arguing that genetic information’s intrinsic moral value
justifies the continued prominence of genetic exceptionalism in bioethics).
113
See Suter, supra note 94; see also Trudo Lemmens, Selective Justice,
Genetic Discrimination, and Insurance: Should We Single Out Genes in Our
Laws?, 45 MCGILL L.J. 347 (2000) (discussing the desirability of geneticspecific legislation in the insurance context); Douglas H. Ginsburg, Genetics
and Privacy, 4 TEX. REV. L. & POL. 17 (2000); Mark A. Rothstein, Genetic
Exceptionalism and Legislative Pragmatism, 35 J.L. MED. & ETHICS 59 (2007);
Lawrence O. Gostin & James G. Hodge, Jr., Genetic Privacy and the Law: An
End to Genetic Exceptionalism, 40 JURIMETRICS J. 21 (1999) (arguing that there
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literature is silent, however, on whether genetic exceptionalism
applies with equal force to the patentability of genes debate. In
other words, assuming that the statutory requirements for
patentability can otherwise be satisfied, should the law reject gene
patents based solely on genetic exceptionalism’s justification that
genes unique characteristics warrant different protections than do
other fields of science?
B. Power Play from the Bench: Myriad’s Insertion of Genetic
Exceptionalism into the Patent Act
The previous sections provide background information to the
reader with regard to the law on gene patents and the story of
genetic exceptionalism’s impact on insurance, discrimination, and
privacy laws. In the recent controversial case on gene patents,
Association for Molecular Pathology v. U.S. Patent and
Trademark Office, 114 patentable subject matter collides with
genetic exceptionalism for the first time, transforming genetic
exceptionalism into a legal principle. In the opinion, Judge Sweet
singles out DNA from other isolated products based purely on
DNA’s information carrying characteristics, while attempting to
invalidate DNA patents under a “product of nature” analysis. 115
The court falls short in its explanation of why other purified or
isolated products of nature continue to be patentable subject
matter. Perhaps influenced by DNA’s mystique, the court reasoned
that genetic patents differ from patents on antibodies, antibiotics,
hormones, metabolites, biologic drugs, and the like, because DNA
is solely the “physical embodiment of information.” 116 Rather than
purely focusing on the chemical makeup of DNA (after all, DNA is
comprised of chemically bound strands of molecules), the court
is no clear demarcation between genetic data and other health information).
114
702 F. Supp. 2d 181 (S.D.N.Y. 2010); referred to herein as “Myriad.”
115
See id.
116
See Noonan, supra note 44, at 30 n.17. As Noonan points out, these
naturally occurring, isolated products are in “substantially homogenous form,
are structurally unchanged from their sources in blood and other bodily fluids,
and are less altered than the cDNAs that are the subject of the claims to isolated
human DNA invalidated by the district court.” Id.
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embraces the genetic exceptionalism ideals by finding that genes
are inherently different and thus deserving of unique treatment
under the Patent Act. 117 Despite whether genetic information
should be treated differently in other contexts—for example with
insurance, discrimination, and privacy laws—Judge Sweet
overlooks the fact that the genetic information itself is not
patented. As such, researchers are able to utilize the genetic
information disclosed in the patent for purposes such as
performing sequence comparisons or detecting genetic
polymorphisms. 118 This section dissects the law on patentable
subject matter from the opinion’s genetic exceptionalism
components, and then evaluates whether the holding can stand
based purely on the legal arguments that remain.
1. Background of BRCA1/2 and the Myriad Litigation
In 1990, a team of geneticists discovered that a mutation in the
BRCA1 gene was linked to an increased risk for developing breast
and ovarian cancers. 119 Of the patients with hereditary breast
cancer, five to ten percent have a substituted allele that inactivates
the BRCA1 gene, leading to an abnormal cellular gene expression
of the protein. 120 If a patient has a mutated gene, she has a lifetime
risk of 40 to 85 percent for developing breast cancer and a risk of
16 to 40 percent for developing ovarian cancer. 121 Other known
factors, such as the type of mutation (e.g., insertion, deletion, or
rearrangement of codons) and family history can impact the
lifetime risk of developing cancer, as well as the likely interaction

117

Some philosophers have viewed genes as more than the “common
heritage of mankind,” arguing that genes are an “un-encloseable commons-bynecessity . . . . free for use by any and all.” David Koepsell, Naturally Occurring
Genes and the Commons by Necessity, 23 GENEWATCH 32, 34 (Oct.-Dec. 2010).
118
Id. at 31.
119
Bryn Williams-Jones, History of a Gene Patent: Tracing the
Development and Application of Commercial BRCA Testing, 10 HEALTH L.J.
123, 131 (2002).
120
Id. at 127.
121
Id.
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with other genes. 122 The BRCA2 gene is also thought to be a
similar acting tumor-suppressing gene. 123
Mark Skolnick, the co-founder of Myriad, sequenced the
BRCA1 gene in August 1994 with the help of a team of
researchers from NIH, the University of Utah, and McGill
University. 124 Following this discovery, Skolnick and Myriad filed
for a U.S. patent claiming the isolated sequence and the associated
mutations as both a “composition of matter” and a “method-ofuse.” 125 The USPTO was quick to issue the patents to Myriad, but
further complicated the patentability of BRCA1 by issuing a
similar patent to OncorMed. 126 OncorMed’s BRCA1 patent
differed only slightly with respect to the mutations claimed,
overlapping in both the diagnostic and therapeutic applications of
the patent. 127 As a result, both patent owners filed infringement
suits against the other, but instead of litigating the issue,
OncorMed settled by selling Myriad its patent on BRCA1 in
1998. 128
Understanding the importance of locating and patenting
BRCA2, Myriad embarked on a race to discovery against a group
of U.K. scientists who were also highly invested in locating the
sequence. On December 21, 1995, the day before the U.K.
scientists were scheduled to publish its discovered BRCA2
sequence in Nature magazine and the day of the U.K.’s planned
press conference, Myriad notified the public that they had
sequenced BRCA2 and had filed for a U.S. patent. 129 Having now
secured patents to both the isolated BRCA1 and BRCA2 genes,
Myriad was poised to control the testing market for breast and
122

Id.
Id.
124
Id. at 131. The founders of Myriad were “focused on the discovery and
commercialization of genes involved in major common disorders including
cancer and heart disease.” Id. at 129 (citation omitted). Myriad now offers an
array of services, ranging from research and development to diagnostics.
125
Id.
126
Id. at 132.
127
Id.
128
Williams-Jones, supra note 119, at 132.
129
Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 202
(S.D.N.Y. 2010).
123
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ovarian cancer and the market for developing therapeutics to treat
patients with one of the mutations. 130
Over the course of the 1990s, Myriad did not assert its
exclusivity rights over its BRCA1/2 patents, but instead allowed
researchers to use the tests under certain circumstances. Myriad
offered to license its patents to the University of Pennsylvania
Genetic Diagnostic Laboratory so that the laboratory could
continue its screening program on BRCA1 and BRCA2. 131 Not
satisfied with the scope of the license, the University and its
physicians rejected the licensing proposal. 132 Myriad subsequently
sent cease-and-desist letters to the University of Pennsylvania and
on August 26, 1998, sent notice that the physicians were infringing
Myriad’s patents and filed the infringement suit in November of
the same year. 133 Although the laboratory was forced to stop
performing tests, Myriad informed the University that it was free
to continue academic research on the genes. 134 A similar course of
conduct—Myriad offering a license and the plaintiffs rejecting the
license—occurred with the other plaintiffs in the case. 135
Myriad asserted seven patents against the plaintiffs, identifying
fifteen claims within those patents that the plaintiffs allegedly
infringed. 136 The claims fell into one of two categories:
composition claims or method-of-use (or process) claims. 137
Because there were several composition claims within the patent,
130

In the years following the issuance of the patents, Myriad developed a
host of tests to screen and diagnose patients with an increased risk for breast
cancer. Among the tests (listed from least to most expensive) include: (1) a
single site test for patients having a family history of the mutation, designed to
identifies carriers; (2) a multisite test that searches for three common mutations
in the Ashkenazi Jewish population; (3) a comprehensive test identifying the full
gene sequence; and (4) a rapid test designed to return the full gene sequence
within seven days. Williams-Jones, supra note 119, at 133-34. Myriad’s tests
were arguably more sensitive than other tests offered at the time because
Myriad’s tests identified each base-pair within the gene. Id.
131
Myriad, 702 F. Supp. 2d at 205.
132
Id.
133
Id.
134
Id.
135
Id.
136
Id. at 212.
137
Id.
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the court provided one composition claim as the categorical
representative, which read: “An isolated DNA coding for a BRCA1
polypeptide, said polypeptide having the amino acid sequence set
forth in SEQ ID NO:2.” 138
Similarly, the court provided a representative methods-of-use
claim for Myriad, which reads: “A method for detecting a germline
alteration in a BRCA1 gene . . . in a human which comprises
analyzing a sequence of a BRCA1 gene or BRCA1 RNA from a
human sample or analyzing a sequence of BRCA1 cDNA . . . .”139
In layman’s terms, the first category of claims at issue covers any
use of the isolated gene itself and the second category of claims at
issue covers methods used to analyze mutations in the gene that
correlate with a predisposition for breast and ovarian cancer. 140
The plaintiffs brought an action for summary judgment against
the USPTO & Myriad asking the court to declare these patents
relating to BRCA1/2 invalid for lack of patentable subject
matter. 141 The plaintiffs urged the court to find that the patents
were improperly issued to cover products of nature, laws of nature,
physical phenomena, and abstract ideas, which offend Article I,
§ 8, Clause 8 of the United States Constitution.142
2. A Closer Look at Judge Sweet’s Analysis in the Myriad
Decision
Judge Sweet crystallized the issue before the court as whether
“isolated human genes and the comparison of their sequences [are]
patentable.” 143 He embarked on his legal inquiry by first
constructing the claims at issue to determine the scope of the
patent protection. The first claim dispute to be resolved involved
the terms “DNA” and “isolated DNA.” 144 The plaintiffs argued
138

Id. (emphasis added).
Id. at 213 (emphasis added).
140
See id. at 211-17.
141
Id. at 184.
142
Id.
143
Id. at 185.
144
Id. at 216. In construing a patent claim, the court applies several cannons
of construction to arrive at a final interpretation. These canons can be broken
139
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that the term “DNA” should be construed to mean “a sequence of
nucleic acids, also referred to as nucleotides.” 145 As Myriad
pointed out, this definition implies that DNA refers to a description
of the sequence of nucleic acids (i.e., information only). 146 Myriad
contended that “DNA” encompasses a “real and tangible molecule,
a chemical composition made up of deoxyribonucleotides linked
by a phosphodiester backbone.” 147 In resolving this dispute in
Myriad’s favor, the court looked at the specification of Myriad’s
patent, which explicitly referred to DNA as a physical
manifestation of the nucleotides such that the DNA could be
separated from the other components of the cells that naturally
accompany DNA. 148 Similarly, the court adopted Myriad’s
definition of “isolated DNA” as set forth in the specification,
which defined isolated DNA as “a DNA molecule which is
substantially separated from other cellular components which
naturally accompany a native human sequence . . . .” 149
The second claim concerned the definition of BRCA1 and
BRCA2. The plaintiffs argued that each meant “a particular
fragment of DNA found on chromosome 17 [13 for BRCA2] that
relates to a person’s predisposition to develop breast and ovarian
cancer.” 150 Once again, however, Myriad acted as its own
lexicographer, defining in the patent specification each gene as “a
human breast cancer predisposing gene . . . some alleles of which
down into two categories, intrinsic and extrinsic evidence, with more weight
given to the former. Some of the intrinsic evidence considered by a court
includes: words of the claims themselves, the written description, and the
prosecution history of the patent. Id. at 214-15. In looking at this evidence, the
court will not read a limitation in a dependent claim into the independent claim,
nor will the court read a limitation from the specification into the claim (but
does read the claim “in light of” the specification). Finally, if the patentee acts as
its own “lexicographer,” then the court will use the patentee’s definition for a
disputed term. The court may also look at the extrinsic evidence available:
dictionaries, treatises, and expert testimony. Usually, extrinsic evidence is used
to inform the judge of the field of science and technology. Id. at 215-16.
145
Id.
146
See id.
147
Id.
148
Id. at 216.
149
Id. at 217.
150
Id.
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cause susceptibility to cancer, in particular breast and ovarian
cancer.” 151 While noting that BRCA1 and 2 are genes normally
integrated into chromosomes 17 and 13 respectively, the court
again adopted Myriad’s construction of the definition. 152
Having construed the claim language, the court moved into the
heart of the analysis: subject matter patentability under § 101 of
the Patent Act, which provides, “Whoever invents or discovers any
new and useful process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof, may obtain a
patent . . . .” 153 Although Congress intended to grant patent
protection broadly, § 101 is not without limits. Specifically, the
Supreme Court has carved out three categories of non-patentable
subject matter: laws of nature, natural phenomena, and abstract
ideas. The reasoning behind these exclusions is that although each
may be “discovered” in a sense, each comprises the basic tools of
science and technological work. 154
Under the heading, “Patentable subject matter must be
‘markedly different’ from a product of nature,” Judge Sweet
emphasized that questions of utility and statutory subject matter
patentability are wholly separate inquiries, and only cases decided
on subject matter grounds are binding on the court. 155 Judge Sweet
relied on Funk Brothers, which he described as holding that the
mixture of bacteria was not patentable subject matter because it
“did not create a state of inhibition or of non-inhibition,” but rather
maintained qualities that were a work of nature. 156 Despite ample
151

Id.
Id.
153
Id. at 218 (emphasis added).
154
Id. at 218-219 (citing Diamond v. Chakrabarty, 447 U.S. 303, 309
(1980)). Recall from discussion supra, Chakrabarty held that a genetically
altered bacterium was patentable subject matter because it had “markedly
different characteristics from any found in nature and one having the potential
for significant utility.”
155
Id. at 219, 222.
156
Id. (citing Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127,
128-31 (1948)). Recall that Funk Brothers was deciding the issue whether the
mixture was an “invention or discovery,” not necessarily whether the mixture
was patentable subject matter. Prior to the Patent Act of 1952, “invention or
discovery” was interpreted as the non-obvious prong for patentability. See Brief
152
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evidence that Funk Brothers was decided on grounds other than
subject matter patentability, 157 however, the court interpreted the
case as standing for the exclusion of natural phenomena from
subject matter patentability. 158
The court next turned in passing to Chakrabarty, which is
arguably more controlling in Myriad since it was decided under
§ 101 of the current Patent Act. 159 While he included some of the
language of the opinion, Judge Sweet omitted any meaningful
discussion on the analysis underlying the Court’s holding. For
instance, he seemingly glossed over the part of the Chakrabarty
opinion that states that without a specifically designed exception
from Congress, § 101 should be construed broadly and in such a
way that includes living things. 160 Since the decision, Chakrabarty
has supported patenting living products that have “markedly
different characteristics from any found in nature and one having
the potential for significant utility.” 161
Throughout the next several pages of the Myriad opinion,
Judge Sweet proffered a litany of cases that essentially require
“something more” than merely isolating or purifying a substance
from its native state to fall within the scope of statutory subject
matter. 162 Read collectively, these cases require that a patentable
product have qualities or characteristics that were absent in its

for Alnylam Pharmaceuticals, Inc. as Amici Curiae Supporting DefendantsAppellants, Ass’n for Molecular Pathology v. Myriad Genetics, Inc. 133 S.Ct.
694 (2012) (No. 12-398) at 8 (“Debunking myths of Funk Bros. Seed Co. v.
Kalo Inoculant Co.”), available at http://patentdocs.typepad.com/files/alnylamamicus-brief.pdf. There is ample language in the Funk Brothers opinion that
suggests the mixture was not patentable because the proffered “invention”
conferred no new quality or use (i.e., obvious) for any one bacterium in the
mixture or for the collective whole. Rather, the mixture merely provided
consumers with a more convenient way to purchase the component bacteria.
157
See id. For a discussion on this very issue, visit the 37 Thoughts legal
blog, available at http://37thoughts.wordpress.com/2010/03/30/save-the-funkbrothers/.
158
Myriad, 702 F. Supp. 2d at 222.
159
Id. at 223.
160
Chakrabarty, 447 U.S. at 318.
161
Id. at 310.
162
Myriad, 702 F. Supp. 2d at 223-28.

2013]

PERSONALIZED MEDICINE, GENETIC EXCEPTIONALISM,
AND THE RULE OF LAW

535

natural form. 163 As examples, the court cited to refined cellulose,
artificial alizarine dye, purified tungsten, and isolated pine needle
fibers, all of which were rejected as non-patentable subject
matter. 164
Turning to precedent relied on by Myriad, Judge Sweet
summarily rejected the applicability of Parke-Davis, which Myriad
asserted as establishing that the purification of a naturally
occurring product (i.e., adrenaline) was patentable subject
matter. 165 He noted that Parke-Davis was decided on novelty—not
subject matter—grounds and was therefore not applicable to the
present case being decided under § 101. 166 In so doing, he cast the
language in Parke-Davis, which stated that “even if [adrenaline]
were merely an extracted product without change, there is no rule
that such products are not patentable,” as dicta. 167 Judge Sweet
went on to distinguish other cases cited by Myriad based on similar
reasoning. 168
Finally, almost as an afterthought, Judge Sweet briefly
addressed Merck & Co., Inc. v. Olin Mathieson Chem. Corp.,169
which held that a higher concentration of purified Vitamin B12—
capable of treating anemia—was a patentable composition of
matter. 170 The purified B12 was created through an artificial
fermentation process that allowed for the production of a greater
concentrated product than the naturally occurring B12 produced by
cows. 171 Because of the different concentration and effectiveness
as a therapeutic agent, the Mathieson court reasoned that the new
product was not the same as the old naturally occurring product,
but rather a “new and useful composition entitled to the protection

163

See id.
See id.
165
See id. at 225.
166
Id at 225-26.
167
Id. at 226 (quoting Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95,
103 (S.D.N.Y. 1911)).
168
Id. at 225-27.
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253 F.2d 156 (4th Cir. 1958).
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Myriad, 702 F. Supp. 2d at 227.
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Mathieson, 253 F.2d at 165.
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of the patent.” 172 Without scratching the surface of the case, Judge
Sweet merely pointed out the court’s conclusion that purified
Vitamin B12 was more than a “mere advance in the degree of
purity of a known product.” 173
3. Genetic Exceptionalism Transcribed into Legal Principle:
Isolated DNA is not “Markedly Different” from Native DNA
After setting forth the legal precedent, Judge Sweet identified
the applicable test for determining the subject matter patentability
of Myriad’s isolated BRCA1 and BRCA2 gene patents. Namely,
whether the isolated DNA claimed in the patent possesses
“markedly different characteristics” from the native (or genomic)
DNA. 174 Focusing on the chemical make-up of DNA, Myriad
argued that the isolated DNA is markedly different because it
differs both structurally and functionally from genomic DNA.175
Instead of looking at the similarities and the differences between
the two compositions, Myriad argued the court should look
exclusively at the differences. 176 Judge Sweet rejected this
approach, citing Supreme Court precedent that requires claims be
considered as a whole. 177 While a correct statement of the law, the
law may be misapplied; reading the claim as a whole means
looking at the entire claim regarding isolated DNA, not the
genomic DNA that falls outside the scope of the patent. 178
At this point in the opinion, Judge Sweet diverges from a
purely legal argument into what is viewed by some as carving out
an exception for gene patents based on the inherent information
carrying function of genes themselves. He explained that focusing
on the chemical nature of DNA “fails to acknowledge the unique
characteristics of DNA that differentiate it from other

172
173
174
175
176
177
178

Id.
Myriad, 702 F. Supp. 2d at 227 (quoting Mathieson, 253 F.2d at 164).
Id. at 227-28.
Id. at 229.
Id.
Id.
See id. at 228.
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compounds.” 179 Without citing any legal authority justifying why
DNA should be considered differently under the Patent Act, he
goes on to explain that even if other chemical compounds contain
information, the information encoded in DNA reflects its primary
biological function: “[DNA] direct[s] the synthesis of . . . proteins,
biological molecules of enormous importance, which catalyze
biological chemical reactions and constitute the major structural
materials of the animal body.” 180 Thus, DNA could be seen as the
“physical embodiment of laws of nature.” 181
Given the unique nature of DNA, Judge Sweet reasoned that
the structural and functional differences raised by Myriad were not
“markedly different.” 182 Rather than explaining why the
differences are not relevant to an inquiry into the nature of native
versus isolated DNA, he jumped to the conclusion that neither is
relevant because of the “overriding importance of DNA’s
nucleotide sequence to both its natural biological function as well
as the utility associated with DNA in its isolated form.” 183 In other
words, because isolated DNA preserves the important
characteristics of native DNA, isolated DNA can never be
“markedly different.” 184 He goes on to state that the “defining
characteristic of DNA in its native and isolated forms mandates the
conclusion that the challenged composition claims are directed to
unpatentable products of nature.” 185
In its attempt to persuade the court, Myriad delineated several
distinctions between isolated DNA and native DNA. First, they
argued, there are structural differences because isolated DNA is
179

Id. In response to biotech’s assertion that invalidating gene patents will
lead to invalidating pharmaceuticals, Judge Sweet states: “The conclusions
reached in this opinion concerning the subject matter patentability of isolated
DNA . . . are based on the unique properties of DNA that distinguish it from all
other chemicals and biological molecules found in nature.” Id. at 228 n. 51
(emphasis added).
180
Id. (internal quotations omitted).
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not associated with chromosomal proteins. 186 The court rejected
this argument, stating it was only a matter of purity. 187 Next,
Myriad asserted that native DNA contains introns (noncoding
regions) that are absent from the isolated or purified DNA, which
only contains the exons (coding regions). 188 However, Judge Sweet
found that because the isolated DNA contains some of the same
gene fragments (e.g., the same fifteen nucleotide sequence), the
two are not sufficiently different. 189 Judge Sweet stated that the
claims covering the compositions of matter for BRCA1/2 (i.e.,
cDNA molecules) cover the same product that is produced by
naturally-occurring splicing within the cell. 190 Yet he failed to
recognize that the isolated DNA—as a chemical molecule—is
much smaller, not three dimensional, and lacks the chemical
complexity of genomic DNA, all properties which permit novel
and innovative uses. 191
Arguably, Myriad’s strongest argument rested with isolated
DNA’s ability to be practically applied in ways that native DNA
cannot. By extracting and significantly altering native DNA,
scientists are able to use the isolated molecules to improve patient
health care. 192 With the adapted DNA, scientists are able to
perform diagnostic tests using the molecule as a probe, primer, or
template for sequencing genes. 193 Likewise, isolated DNA opens
the door to medical treatment options ranging from preventative
care to gene therapy. 194 Without the isolated DNA molecules, none
of these health care innovations would be possible. 195
186

Id. at 228-29.
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See Brief for Am. Intellectual Prop. Law Ass’n as Amici Curiae
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Finally, Judge Sweet hypothesized that a “time may come
when the use of DNA for molecular and diagnostic purposes may
not require such purification.” 196 This consideration runs contrary
to patent law, which requires the evaluation for patentability to
take place at the time of the invention, regardless of any
subsequent innovations. 197
Notwithstanding the newly derived capabilities of isolated
DNA, the court erroneously rejected these differences, instead
electing to focus on the information carrying characteristics of
inherent in the nucleotide sequence. In so doing, Judge Sweet
elevates DNA to a greater status than other chemical molecules—
excepting genetic science from other fields of discovery. There is
nothing in precedent or the Patent Act that demands DNA be
treated differently than the molecules which comprise it. It follows
that if Judge Sweet had not cast DNA as an elite chemical
substance, the decision may have fallen more in line with that of
the Court of Customs and Patent Appeals in In re Bergy. 198
In Bergy, the court was presented with the question whether the
discovery of a biologically pure bacterium for pharmaceutical use,
providing an indispensable medical tool, was patentable. 199 The
court reasoned,
[M]icroorganisms have long been important tools in
the chemical industry, especially its pharmaceutical
branch, and when such a useful, industrial tool –
[the tools used by chemical manufacturers in the
same way as they use chemical elements,
compounds, and compositions] – is invented which
is new and unobvious, so that it complies with those
conditions for patentability, we see no reason to
deprive it or its creator or owner of the protection
196

Myriad, 702 F. Supp. 2d at 232.
See 35 U.S.C. § 103 (stating the time for evaluating obviousness against
prior art is at the time of invention, not the time of the patent application’s
evaluation).
198
596 F.2d 952 (C.C.P.A. 1979) (affirmed sub nom Diamond v.
Chakrabarty, 447 U.S. 303 (1980)).
199
Id.
197
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and advantages of the patent system by arbitrarily
excluding it at the outset from the § 101 categories
of patentable invention on the sole ground that it is
alive. It is because it is alive that it is useful. . . . 200
By analogy, DNA’s chemical characteristics enable it to be
used as a medical tool, but not unless it is isolated and purified.
Without the man-made changes, the DNA molecule is unable and
unreliable as a diagnostic tool. Thus, neither law nor fact supports
arbitrarily excluding isolated DNA from patent protection owing to
the fact that it carries the same information as genomic DNA. As
an Amicus Curie brief eloquently summarized, “By selectively
assigning dispositive importance to one shared characteristic of the
claimed purified/isolated DNA molecules and discounting all the
differences, the District Court adopted precisely the rationale that
Bergy rejected.” 201
CONCLUSION
After reviewing Judge Sweet’s 152-page opinion, the Author
would argue that there is no legal or factual basis for declaring
isolated DNA outside the scope of patentable subject matter.
Instead, it appears that the impetus behind the Myriad decision is
rooted in genetic exceptionalism. By adhering to the principles of
genetic exceptionalism, the opinion tends to overlook legal
precedent to arrive at a conclusion that the nature of DNA as
information carriers naturally exempts itself from patent protection
absent an express exclusion from Congress. One could conclude
that the Myriad decision was largely influenced by the societal,
moral, and ethical issues—not by the legal precedent—raised by
the plaintiffs. The opinion devoted several pages to the negative
impacts that gene patents have on costs and access to health care as
well as the possible chilling effect on research innovation. While
these are important considerations in determining patent policy,
they are not factors to be applied under the Patent Act. If such was
the case, patented and statutorily permissible subject matter—such
200
201

Id. at 975 (emphasis added) (internal citations and quotations omitted).
AIPLA Brief at 17 (citing Bergy, 596 F.2d at 975).
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as pharmaceuticals example—could be invalided solely based on
similar policy concerns. Whether one agrees that genetic
information should be treated different, almost reverently, deciding
whether to adopt genetic exceptionalism is a matter of public
policy rather than legal principle. 202 Thus mandating that the
Patent Act subject matter patentability requirement be interpreted
through the lens of genetic exceptionalism is a power not conferred
to the bench, but rather to Congress.

202

Perhaps Chief Justice Burger stated it best in Chakrabarty, when
addressing the judicial branch’s place in making policy decisions:
The choice we are urged to make is a matter of high policy for
resolution within the legislative process after the kind of
investigation, examination, and study that legislative bodies
can provide and courts cannot. That process involves the
balancing of competing values and interests, which in our
democratic system is the business of elected representatives.
Whatever their validity, the contentions now pressed on us
should be addressed to the political branches of the
Government, the Congress and the Executive, and not to the
courts.
447 U.S. at 317.
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